Press release, Helsinki, 11 June 2026 at 9 AM (EEST)
Nexstim Receives Order for Ten NBS 6 Systems from Distributor
Nexstim Plc ("Nexstim" or "Company") has received an order for ten NBS 6 systems from a distributor. The systems are to be delivered to the United States and European Union during both H1 and H2 2026.
The NBS 6 is a new generation Nexstim system built on Nexstim’s unique, clinically established E-field navigated TMS (transcranial magnetic stimulation) technology. The modular system concept enables system capabilities to expand over time and allows the system to be customized based on the customer’s clinical or research needs.
In Europe, the NBS 6 system is CE-marked for pre-surgical mapping, as well as for post-operative rehabilitation and the treatment of major depression and chronic neuropathic pain. The NBS 6 is FDA-cleared for pre-surgical mapping of the speech and motor cortices of the brain, as well as for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in adult and adolescent patients. The NBS 6 is also FDA-cleared as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD).
The systems ordered include diagnostic features as well as therapy modules.
Mikko Karvinen, CEO of Nexstim, comments: “We are very happy to see continued demand for our NBS 6 system globally through our distributor network. Orders like this reflect the growing trust in our technology and its versatility in both diagnostic and therapeutic use. We are proud to support our partners and their customers in expanding access to advanced nTMS solutions.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com.